Intravenous artesunate plus oral dihydroartemisinin–piperaquine or intravenous quinine plus oral quinine for optimum treatment of severe malaria: lesson learnt from a field hospital in Timika, Papua, Indonesia

被引:0
作者
Silvester Alexandro Sikora
Jeanne Rini Poespoprodjo
Enny Kenangalem
Daniel A. Lampah
Paulus Sugiarto
Ida Safitri Laksono
Riris Andono Ahmad
E. Elsa Herdiana Murhandarwati
机构
[1] Universitas Gadjah Mada,Postgraduate Programme of Tropical Medicine, Faculty of Medicine, Public Health and Nursing
[2] Universitas Gadjah Mada,Department of Paediatrics, Faculty of Medicine, Public Health and Nursing
[3] Timika Malaria Research Programme,Center for Tropical Medicine, Faculty of Medicine, Public Health and Nursing
[4] Papuan Health and Community Development Foundation,Dept. of Epidemiology, Biostatistics and Population Health, Faculty of Medicine, Public Health and Nursing
[5] Mimika District Hospital,undefined
[6] Mitra Masyarakat Hospital,undefined
[7] Universitas Gadjah Mada,undefined
[8] Universitas Gadjah Mada,undefined
来源
Malaria Journal | / 18卷
关键词
Severe malaria; Artesunate; Quinine; Dihydroartemisinin–piperaquine; Length of stay; Recurrence;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 140 条
[1]  
Tjitra E(2008)Multidrug-resistant PLoS Med 5 e128-725
[2]  
Anstey NM(2017) associated with severe and fatal malaria: a prospective study in Papua, Indonesia BMC Infect Dis 17 794-1657
[3]  
Sugiarto P(2012)Intravenous artesunate plus Artemisinin-based Combination Therapy (ACT) or intravenous quinine plus ACT for treatment of severe malaria in Ugandan children: a randomized controlled clinical trial PLoS ONE 7 e45645-1062
[4]  
Warikar N(2005)Clinical features of severe malaria associated with death: a 13-year observational study in the Gambia Lancet 366 717-550
[5]  
Kenangalem E(2010)Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial Lancet 376 1647-359
[6]  
Karyana M(2018)Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial Clin Infect Dis 67 1053-S90
[7]  
Byakika-Kibwika P(2015)A competing-risk approach for modeling length of stay in severe malaria patients in South-East Asia and the implications for planning of hospital services Malar J 14 226-16
[8]  
Achan J(2008)An operational comparative study of quinine and artesunate for the treatment of severe malaria in hospitals and health centres in the Democratic Republic of Congo: the MATIAS study Malar J 7 148-1422
[9]  
Lamorde M(2018)Malaria morbidity in Papua Indonesia, an area with multidrug resistant Am J Trop Med Hyg 98 543-187
[10]  
Karera-Gonahasa C(2019) and PLoS Med 16 e1002815-765